Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112


Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Torimoto K, Miyake M, Anai S, Fujii T, Hasegawa M, Fujimoto K.

J Contemp Brachytherapy. 2019 Oct;11(5):409-416. doi: 10.5114/jcb.2019.88142. Epub 2019 Oct 30.


Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz136. doi: 10.1093/jjco/hyz136. [Epub ahead of print]


Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non-small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher.

Anai S, Ibusuki R, Takao T, Sakurai Y, Hisasue J, Takaki Y, Hara N.

Thorac Cancer. 2019 Dec;10(12):2282-2288. doi: 10.1111/1759-7714.13222. Epub 2019 Oct 21.


A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K.

Diagnostics (Basel). 2019 Sep 4;9(3). pii: E112. doi: 10.3390/diagnostics9030112.


Evaluation of Preoperative Abdominal Adipose Tissue-, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors.

Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1706-1716. doi: 10.1016/j.transproceed.2019.04.057.


Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K.

Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.


The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.


Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.

Kadono Y, Konaka H, Izumi K, Anai S, Fujimoto K, Ishibashi K, Kawai N, Kato T, Iba A, Masumori N, Yoshimura K, Mizokami A.

Contemp Clin Trials Commun. 2019 Jun 26;15:100403. doi: 10.1016/j.conctc.2019.100403. eCollection 2019 Sep.


Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.

Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K.

Diseases. 2019 Jun 18;7(2). pii: E44. doi: 10.3390/diseases7020044.


Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer.

Miyake M, Owari T, Tomizawa M, Matsui M, Nishibayashi N, Iida K, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K.

Urol J. 2019 May 5;16(2):145-151. doi: 10.22037/uj.v0i0.4531.


Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.

Hori S, Tanaka N, Nakai Y, Morizawa Y, Tatsumi Y, Miyake M, Anai S, Fujii T, Konishi N, Nakagawa Y, Hirao S, Fujimoto K.

Res Rep Urol. 2019 Mar 19;11:61-68. doi: 10.2147/RRU.S193933. eCollection 2019.


Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma.

Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Onishi S, Nakai Y, Anai S, Tanaka N, Fujimoto K.

Oncol Lett. 2019 Apr;17(4):4004-4010. doi: 10.3892/ol.2019.10057. Epub 2019 Feb 20.


Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens.

Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, Furuya H, Rosser CJ, Fujimoto K.

Cells. 2019 Mar 2;8(3). pii: E212. doi: 10.3390/cells8030212.


Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.

Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ.

Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.


Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.


The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers.

Miyake M, Fukui S, Gotoh D, Matsumura Y, Samma S, Matsumoto Y, Momose H, Hori S, Watanabe S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K.

World J Surg Oncol. 2019 Feb 18;17(1):35. doi: 10.1186/s12957-019-1581-0.


Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.

N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.


Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy.

Itami Y, Miyake M, Tatsumi Y, Gotoh D, Hori S, Morizawa Y, Iida K, Ohnishi K, Nakai Y, Inoue T, Anai S, Tanaka N, Shimada K, Hirao S, Fujimoto K.

Int J Clin Oncol. 2019 May;24(5):533-545. doi: 10.1007/s10147-018-01381-y. Epub 2019 Jan 2.


Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Hori S, Morizawa Y, Tatsumi Y, Hasegawa M, Fujii T, Fujimoto K.

J Radiat Res. 2019 Mar 1;60(2):270-280. doi: 10.1093/jrr/rry101.


Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.

Onishi K, Tanaka N, Miyake M, Nakai Y, Anai S, Torimoto K, Yamaki K, Asakawa I, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Clin Transl Radiat Oncol. 2018 Nov 17;14:51-58. doi: 10.1016/j.ctro.2018.11.001. eCollection 2019 Jan.

Supplemental Content

Loading ...
Support Center